ICER to Use Aetion Observational RWE to Update Value Assessment of Treatments for Hereditary Angioedema - New ICER pilot will incorporate more than 24 months of observational real-world demographic, utilization, and cost data to further clarify therapies' value - Through continued use of the Aetion Evidence Platform®, ICER advances the use of transparent, replicable real-world evidence in health technology assessment News provided by Share this article ICER) today announced it is using observational real-world evidence (RWE) to update its 2018 assessment of three therapies for long-term prophylaxis against hereditary angioedema (HAE) attacks: lanadelumab (Takhzyro®, Takeda), and two C1 esterase inhibitors (Haegarda®, CSL Behring; and Cinryze®, Takeda).